454182-03-7

Basic information

• Product Name: 3-benzyloxy-6-mercapto-pyridazine
• Synonyms: 3-benzyloxy-6-mercapto-pyridazine
• CAS NO: 454182-03-7
• Molecular Weight: 218.279
• Mol File: 454182-03-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-benzyloxy-6-mercapto-pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyloxy-6-mercapto-pyridazine(454182-03-7)
• EPA Substance Registry System: 3-benzyloxy-6-mercapto-pyridazine(454182-03-7)

Safety Data

• Hazardous Substances Data: 454182-03-7(Hazardous Substances Data)

Upstream product

• 91063-19-3 3-(benzyloxy)-6-chloropyridazine 
• 78-93-3 butanone 

Relevant articles and documents

Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors

This invention relates to novel sulfonyl pyridazinone compounds useful as aldose reductase inhibitors in the treatment or prevention of certain complications arising from diabetes mellitus, pharmaceutical compositions comprising the sulfonyl pyridazinone, pharmaceutical compositions comprising a combination of the sulfonyl pyridazinone together with a second pharmaceutical agent, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds in combination with a second pharmaceutical agent and compounds useful as intermediates for preparing the sulfonyl pyridazinone compounds of this invention.

Pyridazinone aldose reductase inhibitors

The present invention relates to novel pyridazinone compounds, pharmaceutical compositions comprising those compounds and to methods of using such compounds and compositions to inhibit aldose reductase, lower sorbitol levels and, thus, lower fructose levels, and/or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. This invention also relates to methods of affording cardioprotection to subjects not suffering from diabetes. This invention also relates to pharmaceutical compositions and kits comprising a combination of an aldose reductase inhibitor (ARI) of this invention and a sorbitol dehydrogenase inhibitor and to methods of using such compositions or kits to treat or prevent the above diabetic complications in mammals. This invention also relates to other combinations with the ARIs of this invention, including combinations with adendsine agonists; NHE-1 inhibitors; glycogen phosphorylase inhibitors; selective serotonin reuptake inhibitors; GABA agonists; antihypertensive agents; 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; phosphodiesterase-5 inhibitors; and to glucose lowering agents.

Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors

Compounds of the formula (I): a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug, wherein R1, R2, X and Y are as defined in the claims are aldose reductase inhibitors useful in the treatment or p